Physician profile
Cheri C Johnston
NPI 1639186455
$10,817.22
in general payments reported to CMS, 2019-2025
66 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $1,841 · 2021: $2,495 · 2022: $2,104 · 2023: $1,263 · 2024: $1,196 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,940 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,939.58 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,049.06 | 2019-2025 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $929.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $828.09 | 2019-2024 | Emgality, Mounjaro, Reyvow |
| Abbvie INC. | $779.41 | 2019-2025 | |
| Ucb, INC. | $590.43 | 2019-2024 | Rystiggo |
| Allergan, INC. | $475.23 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $437.42 | 2020-2024 | Austedo Xr |
| Pfizer INC. | $410.04 | 2019-2025 | |
| Neurelis, INC. | $356.06 | 2020-2024 | Valtoco |
| Lundbeck LLC | $337.73 | 2020-2023 | Vyepti |
| Genzyme Corporation | $307.80 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $303.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $286.47 | 2019-2024 | Veozah |
| Csl Behring | $238.80 | 2019-2023 | Hizentra |
| Amarin Pharma, INC. | $220.62 | 2019-2023 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.